Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2019, Vol. 41 ›› Issue (2): 261-266.doi: 10.3881/j.issn.1000-503X.10868

• Review Article • Previous Articles     Next Articles

Advances in Retinopathy of Prematurity

XU Xiaoxuan1,WU Yajun1,WU Hongyun2,HU Yuxiang1,CHENG Yi1,YAN Li1,RAO Jie1,WU Na1,WU Xiaorong1()   

  1. 1 Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China
    2 Department of Ophthalmology,Ganzhou People’s Hospital,Ganzhou,Jiangxi 341000,China;
  • Received:2018-09-23 Online:2019-04-28 Published:2019-05-07
  • Contact: Xiaorong WU E-mail:wxr98021@126.com
  • Supported by:
    National Natural Sciences Foundation of China(81760179);Supported by National Natural Sciences Foundation of China(81360151);Natural Sciences Foundation of Jiangxi Province(20171BAB205046);Health Development Planning Commission Sciences Foundation of Jiangxi Province(20185118);Traditional Chinese Medicine Scientific Research Project of Health and Family Planning Commission of Jiangxi Provincial(2017A001);Jiangxi Province Education Department Key Foundation(GJJ160033);Jiangxi Provincial Grassroots Health Appropriate Technology “Spark Promotion Plan” Project(20188007);Technology and Science Foundation of Jiangxi Province(20141BBG70027);Jiangxi Province Education Department Scientific Research Foundation(GJJ13147);Program of Teaching Reform Research of Degree and Postgraduate Education in Jiangxi Province(JXYJG-2018-016);Nanchang University Postgraduate Case Construction Project(9202-0210210802)

Abstract:

Retinopathy of prematurity(ROP)is a pathological neovascularization with fibrotic changes in the fundus of premature infants.It is a major cause of preventable blindness in children in both developing and developed countries.Treatment of ROP has long been a hot research topic in ophthalmology and pediatrics.With a clearer knowledge of the pathogenesis of ROP,more basic and clinical studies have been carried out.The anti-vascular endothelial growth factor therapy and surgical treatment have become mature strategies,and a variety of therapeutic drugs including insulin-like growth factor-1,transforming growth factor-β,polyunsaturated fatty acids,and β-adrenergic receptor blockers have been developed.This article reviews the recent advances in ROP.

Key words: retinopathy of prematurity, anti-vascular endothelial growth factor, insulin-like growth factor-1, transforming growth factor-β, polyunsaturated fatty acids

CLC Number: